Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imlunestrant + abemaciclib
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Imlunestrant + abemaciclib is a **combination of imlunestrant**, a next-generation, oral, brain-penetrant selective estrogen receptor degrader (SERD) and pure estrogen receptor antagonist, and **abemaciclib**, a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. This combination is designed to deliver continuous estrogen receptor inhibition—including in cancers harboring *ESR1* mutations—while also blocking cell cycle progression via CDK4/6 inhibition. The combination demonstrated significantly improved progression-free survival compared to imlunestrant alone in patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer that recurred or progressed following endocrine therapy. Safety was consistent with known profiles, with predominantly low-grade adverse effects.
- Brand names
- Verzenio
- Other names
- Imlunestrant plus abemaciclibIMPATIENS regimen
02
Targets
CDK6 (Cyclin-dependent kinase 6)ESR2 (ERβ)ESR1 (ERα)CDK4 (Cyclin-dependent kinase 4)
Beyond the preview
Go deeper on imlunestrant + abemaciclib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imlunestrant + abemaciclib.